Genmab A/S (OTCMKTS:GNMSF) Shares Gap Down - Here's What Happened

Key Points

• Genmab A/S shares opened sharply lower, gapping down from $275.00 to $259.3188 and trading about 4.2% lower in Friday premarket activity.
• The company’s latest quarterly earnings were disappointing, with EPS of $0.55 versus the $3.10 consensus estimate, though revenue of $1.06 billion slightly beat expectations.
• Genmab, a Denmark-based biotechnology company focused on antibody therapeutics, has a market cap of about $15.97 billion and is trading below both its 50-day and 200-day moving averages.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) shares gapped down prior to trading on Friday . The stock had previously closed at $275.00, but opened at $259.3188. Genmab A/S shares last traded at $259.3188, with a volume of 8,005 shares.

Genmab A/S Stock Down 4.2%

The firm has a market cap of $15.97 billion, a P/E ratio of 16.75 and a beta of 0.82. The firm's 50-day moving average price is $275.03 and its 200 day moving average price is $300.22. The company has a debt-to-equity ratio of 0.86, a current ratio of 2.02 and a quick ratio of 2.01.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last announced its quarterly earnings data on Tuesday, February 17th. The company reported $0.55 earnings per share for the quarter, missing the consensus estimate of $3.10 by ($2.55). Genmab A/S had a net margin of 25.89% and a return on equity of 17.35%. The firm had revenue of $1.06 billion during the quarter, compared to the consensus estimate of $1.05 billion.

About Genmab A/S

Genmab A/S is a biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer and other serious diseases. The company's core expertise lies in its proprietary antibody platforms, including DuoBody®, HexaBody® and HexElect®, which enable the design and engineering of novel bispecific and enhanced-effector antibodies. Genmab's science-driven approach integrates advanced protein engineering with insights into tumor biology to generate candidates that can engage the immune system, disrupt disease pathways and offer potential safety and efficacy advantages over conventional therapies.

Founded in 1999 and headquartered in Copenhagen, Denmark, Genmab has grown into a global organization with research and development facilities in Utrecht, the Netherlands, and commercial and clinical support offices in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.